Presentation NY Valves 2024 Modern Era Clinical Trial Strategies For Cerebral Embolic Protection Devices Presenter: Alexandra J. Lansky June 05, 2024
Presentation NY Valves 2024 Procedural Clipping Strategy for Tricuspid TEER: Results From the TRILUMINATE Pivotal Trial Presenter: Matthew J. Price June 05, 2024
Presentation NY Valves 2024 Practical Tips for Cerebral Embolic Protection: From Clinical Trials to Clinical Practice Presenter: Amar Krishnaswamy June 05, 2024
Presentation NY Valves 2024 12-Month Clinical Outcomes of K-Clip® System Transcatheter Tricuspid Annuloplasty Multicenter Pivotal Trial Presenter: Guangyuan Song June 05, 2024
Presentation NY Valves 2024 First-in-Human Clinical Trial of a Robotic TEE System for Diagnostics and Interventional Guidance (ROB'E) Presenter: Jury Schewel June 05, 2024
Presentation NY Valves 2024 Late Clinical Outcomes With Balloon Expandable Valves in Small Annulus Patients From the PARTNER Trials Presenter: Rebecca T. Hahn June 05, 2024
Presentation NY Valves 2024 Impact of Cerebral Embolic Protection Devices on Disabling Stroke After Transcatheter Aortic Valve Replacement: Results From the STS/ACC TVT Registry Presenter: Neel Butala June 05, 2024
Presentation NY Valves 2024 Predictors of Bioprosthetic Valve Dysfunction From the Randomized SMART Trial Presenter: Howard C. Herrmann June 05, 2024
Presentation NY Valves 2024 A Randomized Comparison of TAVR and SAVR in Low-Risk Patients Aged 70 Years or Younger: Results From the NOTION-2 Trial Presenter: Ole De Backer June 05, 2024
Presentation EuroPCR 2024 Impact of valve type and anaesthesia strategy for TAVI – 5-year results of the SOLVE-TAVI trial Presenter: Hans-Josef Feistritzer May 14, 2024
Presentation ACC 2024 Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC) Presenter: Rasha K. Al-Lamee April 08, 2024
Presentation ACC 2024 Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial Presenter: David E. Kandzari April 08, 2024
Presentation ACC 2024 Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients at High Risk of Cardiovascular Events: The BE ACTIVE Randomized Controlled Trial Presenter: Alexander Fanaroff April 07, 2024
Presentation ACC 2024 Main Results From The Step-hfpef Dm Trial Presenter: Mikhail Kosiborod April 06, 2024
Presentation ACC 2024 Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Presenter: Michael J. Koren April 06, 2024
Presentation THT 2024 Shock-Phenotype Matching Using Real-World Evidence: A New Paradigm for Prospective Enrollment in Clinical Trials of Acute MCS Devices in Cardiogenic Shock Presenter: James W. Schurr March 06, 2024
Presentation THT 2024 The Conundrum of Clinical Trials in Cardiogenic Shock Presenter: JoAnn Lindenfeld March 06, 2024
Presentation THT 2024 Impact Of Rapid Up-Titration of Guideline-Directed Medical Therapies On Quality of Life: Insights From The STRONG-HF Trial Presenter: Kamile Cerlinskaite-Bajore March 06, 2024
Presentation THT 2024 AI Assisted Identification of Super responders for Ultrafiltration can Reduce 90-Day Readmission Rates: Evidence from AVOID-HF Trial Presenter: Deya Alkhatib March 06, 2024